What Colofac Retard Treats: Main Uses and Benefits

Colofac retard is considered relevant for managing symptoms related to functional bowel disorders. It is relevant across therapeutic domains characterized by heightened physiological activity and discomfort in the gut.

This medication may be part of the symptomatic management for conditions such as Irritable Bowel Syndrome (IBS) and other chronic functional disturbances of the colon. The core therapeutic focus is relevant for easing painful abdominal cramping, intestinal spasms, and abdominal discomfort. It is applied in conditions characterized by recurrent, episodic symptom patterns that may create noticeable interference with daily functioning.

The benefit is that it may provide supportive therapeutic relief to contribute to easing the symptom burden caused by these chronic conditions. This relief may help with managing symptom intensity and may assist patients in coping more steadily with difficult episodes.

“The primary goal is the symptomatic relief of symptoms related to heightened muscular activity and discomfort.”

The modified-release formulation is typically relevant in clinical scenarios requiring sustained symptomatic support. This design may contribute to improving day-to-day comfort, as it provides supportive relief when symptoms interfere with daily functioning.

---

Quick Fact: Support for Easing Intestinal Spasms

Colofac retard is permitted for use in adults, including the elderly, but its eligibility profile is strictly defined by regulatory documents.

Populations Who Must Not Use the Medicine

The medicine is contraindicated for individuals with a known hypersensitivity (allergy) to mebeverine hydrochloride or any of its inactive ingredients. Use is also contraindicated in patients with certain hereditary metabolic disorders, such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, due to excipient content.

Age and Reproductive Restrictions

Use is not recommended for children and adolescents below 18 years of age. This restriction is due to insufficient regulatory data to establish safety and efficacy in the pediatric population.

The medicine should not be used by women who are pregnant or breast-feeding. Mebeverine is not recommended during pregnancy due to limited data, and its use during lactation is restricted because it is unknown if the substance or its metabolites are excreted in human milk.

Regulatory documentation confirms that no dosage adjustment is deemed necessary for patients with renal or hepatic impairment, indicating these organ conditions do not typically impose an eligibility restriction.

Interactions with other medicines and products

Official regulatory documents emphasize the general lack of detailed interaction studies with other medicinal products for Colofac retard (mebeverine hydrochloride).

According to the Summary of Product Characteristics (SmPC), no formal interaction studies have been performed with other medicines. The data available for Mebeverine's safety profile is largely based on post-marketing experience.

Specific Interaction Findings

Substance Category	Official Regulatory Statement
Other Medicinal Products	No documented interaction studies have been performed.
Alcohol (Ethanol)	Official studies in animals have demonstrated the absence of any interaction between mebeverine hydrochloride and ethanol.
Food / Herbal Products	No specific interaction data is documented or stated in the core regulatory label.

Interaction Considerations for Specific Populations

Regulatory authorities state that based on available post-marketing data, no specific interaction risk has been identified for elderly patients or patients with renal or hepatic impairment. Consequently, no specific dosage adjustments related to potential interactions are deemed necessary for these groups, though formal posology studies were not conducted.

Clinical Context

The structure of the official interaction profile indicates that there are no explicit warnings, restrictions, or required timing separations based on pharmacokinetic or pharmacodynamic interactions with co-administered drugs. The primary regulatory statement regarding interactions is the confirmation of no observed interaction with alcohol.

Direct Modulation of Muscle Cell Excitability

The core mechanism of mebeverine involves acting directly on the smooth muscle fibers of the gut wall. It primarily achieves this by blocking voltage-dependent calcium channels and stabilizing the muscle cell membrane through Na^+ channel inhibition. This dual interaction restricts the influx of calcium ions, which are essential for triggering contraction, which results in a direct reduction of electrical excitability within the intestinal muscle tissue.

---

Polyvalent Action and Physiological Specificity

The drug's mechanism is polyvalent, meaning it targets multiple pathways simultaneously to modulate muscle function. The action potentiates local inhibitory signaling and exerts a minor antagonistic effect on muscarinic receptors. The action avoids the widespread suppression of muscle function typically associated with non-selective mechanisms. This combination results in the physiological outcome of decreased muscle overactivity while maintaining the muscle's capacity for functional motility.

---

⏳ Sustained Effect via Controlled Delivery

The modified-release (retard) formulation is integral to the drug's sustained physiological effect. It ensures the active molecule is delivered slowly and consistently across the gastrointestinal tract, maintaining a stable local concentration. This controlled availability is necessary to sustain the localized ion channel blockade and muscle modulation. The mechanism provides sustained modulation of muscle hyperactivity over an extended duration.

How to Use Colofac retard

The usage of Colofac retard (Mebeverine hydrochloride 200 mg modified-release capsules) is governed by specific administration protocols. The medicine is strictly for oral administration and the integrity of the capsule is crucial for its function.

Administration Protocol and Timing

The standard adult dosing regimen involves taking one 200 mg capsule twice daily, resulting in a maximum total daily intake of 400 mg. To facilitate the prolonged-release action, the capsule must be swallowed whole and should not be chewed, crushed, or broken. Each dose is typically taken with a sufficient amount of water, such as 100 ml.

The timing of administration is specifically tied to meals; the capsule should be taken preferably 20 minutes before a meal. The twice-daily frequency generally ensures an approximate 12-hour interval between the morning and evening doses.

Dosing Adjustments and Duration

No specific dose adjustment is considered necessary for older adults (the elderly) or for patients with either renal or hepatic impairment. Colofac retard is not recommended for use in children and adolescents below 18 years due to insufficient data supporting its safety and efficacy in that age group.

If a dose is missed, the user should not take a double dose to compensate. Instead, the user should simply continue with the next scheduled dose at the usual time. The medicine is generally intended for ongoing use as part of symptomatic management, and the overall duration of use is typically not limited.

Research Evidence / Overview of Studies for Colofac Retard

Evidence for Use in Irritable Bowel Syndrome (IBS)

Research for mebeverine, the active ingredient in Colofac retard, has primarily been conducted using short-term Randomized Controlled Trials (RCTs). These are common study designs used in research exploring how symptoms change over time when compared against a control group, such as placebo. Research monitored outcomes related to physical discomfort, specifically tracking patient-reported scores for the frequency and intensity of abdominal pain and cramping. Other research, including Systematic Reviews and Meta-analyses, has combined and evaluated the results of multiple smaller trials.

Studies monitored measurements concerning pain scores during the study period in the short-term follow-up (typically 4 to 12 weeks). These findings contribute to the broader evidence landscape concerning short-term patterns observed in pain scores associated with IBS. However, when research looked at more general outcomes, such as a patient's global symptom assessment score, findings were not always consistent across different systematic reviews. This suggests that the measured patterns for overall assessment appear to be variable.

Evidence for Use in Functional Bowel Disorders and Spasms After Cholecystectomy

Mebeverine was studied for conditions characterized by fluctuating or episodic manifestations beyond typical IBS, including general functional disturbances of the colon. For patients experiencing gastrointestinal spasms after undergoing cholecystectomy (gallbladder removal), specific clinical trials have also been conducted. These studies focused on measuring patient-reported outcomes describing perceived discomfort and monitoring how spasms changed over a defined time interval. Evidence remains limited for this specific application compared to the research volume for IBS.

What is Still Uncertain About Colofac Retard Research

Despite the existing body of evidence, several key research gaps remain. Evidence quality varies across studies, and many older trials had small sample sizes. Crucially, there is limited information for long-term outcomes, and the research does not definitively determine whether an individual's response will be sustained over prolonged periods. Data for certain groups remain insufficient, particularly concerning the patterns of use in specific populations like children or different IBS subtypes.

Common questions about Colofac retard (FAQ)

---

Q: How should I store Cialis?

Official product information states that CIALIS storage is recommended at 25°C (77°F). Brief temperature excursions are permitted, allowing the medicine to be stored between 15°C and 30°C (59°F and 86°F).

---

Q: Can I drink alcohol while taking Cialis?

Regulatory documents indicate that consuming substantial amounts of alcohol (five units or more) alongside CIALIS may increase the risk of certain side effects. These effects could include signs of orthostatic hypotension, such as a drop in standing blood pressure, increased heart rate, dizziness, and headache.

---

Q: Does Cialis make you sleepy?

The official safety information for CIALIS lists somnolence (drowsiness or sleepiness) as a reported adverse reaction. This finding is based on postmarketing reports, which are noted alongside other central nervous system effects such as dizziness and headache.

---

Q: Can children 2 years old use it?

According to the official prescribing information, CIALIS is not indicated for use in pediatric patients. Regulatory documents state that safety and effectiveness in pediatric patients have not been established.

---

How to Store and Dispose of Colofac Retard

The storage and disposal of Colofac Retard (mebeverine hydrochloride modified-release capsules) are governed by strict official requirements.

Storage Conditions

Condition	Requirement
Temperature	Store below 30 C (do not store above 30 C)
Protection	Store in the original package to protect from moisture
Prohibited	Do not refrigerate or freeze
Child Safety	Keep out of the sight and reach of children

Stability and Disposal

The approved shelf-life is 36 months when the medicine is stored under the mandatory conditions. For disposal, unused or expired product and waste material must be disposed of in accordance with local requirements.

The regulatory instructions state that medicines must not be thrown away via wastewater or household waste.